About ustekinum ab
Interleukin-12/23 monoclonal antibody
Used for
- Moderate-to-severe Crohn’s disease in adults
- Moderate-to-severe ulcerative colitis in adults
Usual adult dose
Crohn’s disease or ulcerative colitis: one weight-based intravenous induction dose, followed by subcutaneous maintenance dosing after 8 weeks.
Common side effects
- Infections, including upper respiratory infections
- Headache
- Nausea
- Infusion reactions
Important warnings
- Screen for tuberculosis before treatment; avoid use with active infection.
- Serious infections and some cancers have been reported.
- Avoid live vaccines during treatment.
- Intravenous induction should be given by a healthcare professional.
Pregnancy
Human pregnancy information is limited; use when benefits outweigh potential risks.
Breastfeeding
It is unknown whether ustekinumab passes into human milk; discuss potential benefits and risks.
Interactions
- Avoid live vaccines during treatment.
- Other immunosuppressive medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.